A new oral drug helped people with type 2 diabetes lose significant weight in a major trial.
Patients taking orforglipron lost up to eight percent of their body weight within one year.
The pill activates GLP-1 receptors, lowers blood sugar, and reduces appetite.
Patients can take it without fasting, which simplifies daily use.
In the study, orforglipron outperformed oral semaglutide for weight loss and glucose control.
However, more participants stopped treatment because of stomach-related side effects.
Regulators have not yet approved the drug.
Researchers still need long-term safety and cardiovascular data.
Experts believe effective tablets could replace many injections in the future.
They expect these therapies to become central treatments for type 2 diabetes.
